Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MBOT

MBOT - Microbot Medical Inc Stock Price, Fair Value and News

$1.90-0.07 (-3.55%)
Market Closed

Price Targets

MBOT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBOT Price Action

Last 7 days

-5.9%

Last 30 days

-10.0%

Last 90 days

-12.0%

Trailing 12 Months

-1.5%

MBOT RSI Chart

MBOT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBOT Valuation

Market Cap

127.6M

Price/Earnings (Trailing)

-9.76

Price/Sales (Trailing)

1.2K

Price/Free Cashflow

-11.58

MBOT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

MBOT Fundamentals

MBOT Revenue

Revenue (TTM)

114.2K

MBOT Earnings

Earnings (TTM)

-13.1M

Earnings Growth (Yr)

-11.26%

Earnings Growth (Qtr)

-2.2%

MBOT Profitability

Return on Equity

-16.71%

Return on Assets

-15.99%

Free Cashflow Yield

-8.64%

MBOT Investor Care

Shares Dilution (1Y)

296.63%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2016119.3K118.5K114.2K0
20151.4M994.0K555.5K116.9K
2014943.5K684.8K442.0K1.0M
20131.0M1.0M1.1M1.2M
20121.6M1.7M1.7M1.4M
20111.4M1.4M1.4M1.2M
201001.1M1.3M1.4M
2009000992.9K
Get all data in R, Python etc through our Historical Stock Data APIs

About Microbot Medical Inc

MBOT
Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, a robotic system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination. In addition, it provides One & Done Technology, an endovascular robotic system for a range of applications in cardiovascular, peripheral vascular, and neurovascular spaces; and NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. Further, the company offers ViRob, an autonomous crawling micro-robot which can be controlled remotely to navigate and crawl in different natural spaces within the human body, including blood vessels, digestive tract, and respiratory system, as well as artificial spaces, such as shunts, catheters, ports, etc. Additionally, it provides ipCAT, a disposable self-propelled locomotive device that is designed to advance in tubular anatomies. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is headquartered in Hingham, Massachusetts.
 CEO
 WEBSITEhttps://microbotmedical.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES18

Microbot Medical Inc Frequently Asked Questions

MBOT is the stock ticker symbol of Microbot Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Microbot Medical Inc is 127.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MBOT's fair value in chart for subscribers.

The fair value guage provides a quick view whether MBOT is over valued or under valued. Whether Microbot Medical Inc is cheap or expensive depends on the assumptions which impact Microbot Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBOT.

As of Wed Jan 28 2026, MBOT's PE ratio (Price to Earnings) is -9.76 and Price to Sales (PS) ratio is 1.24 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBOT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Microbot Medical Inc has provided -0.434 (multiply by 100 for percentage) rate of return.